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Abstract
Introduction: Familial glucocorticoid deficiency, or hereditary unresponsiveness to adrenocorticotropic hormone, is
a rare autosomal recessive disease characterized by glucocorticoid deficiency in the absence of mineralocorticoid
deficiency. It may present in infancy or early childhood with hyperpigmentation, failure to thrive, recurrent
infections, hypoglycemic attacks and convulsions that may result in coma or death. Here, we report the case of an
18-month-old Egyptian boy with familial glucocorticoid deficiency.
Case presentation: An 18-month-old Egyptian boy was referred to our institution for evaluation of generalized
hyperpigmentation of the body associated with recurrent convulsions; one of his siblings, who had died at the age
of nine months, also had generalized hyperpigmentation of the body. The initial clinical examination revealed
generalized symmetrical deep hyperpigmentation of the body as well as hypotonia, normal blood pressure and
normal male genitalia. He had low blood glucose and cortisol levels, normal aldosterone and high
adrenocorticotropic hormone levels. Based on the above mentioned data, a provisional diagnosis of familial
glucocorticoid deficiency was made, which was confirmed by a molecular genetics study. Oral hydrocortisone
treatment at a dose of 10 mg/m
2/day was started. The child was followed up after two months of treatment; the
hyperpigmentation has lessened in comparison with his initial presentation and his blood sugar and cortisol levels
were normalized.
Conclusion: Familial glucocorticoid deficiency is a rare, treatable disease that can be easily missed due to
nonspecific presentations. The consequences of delayed diagnosis and treatment are associated with high rates of
morbidity and mortality.
Introduction
Familial glucocorticoid deficiency (FGD) is a rare auto-
somal recessive disease resulting from resistance to the
action of adrenocorticotropic hormone (ACTH) on the
adrenal cortex, which leads to isolated glucocorticoid
deficiency with normal mineralocorticoid secretion [1].
FGD is a rare disease; its exact incidence is unknown
and only isolated case reports are documented. FGD
(OMIM 202200) was first described by Shepard et al. in
1959 [2]. Pathologic evaluation of children affected with
this disorder reveals that the zona glomerulosa of the
adrenal glands is well preserved while the zona fascicu-
lata and zona reticularis are markedly atrophic. These
changes are accompanied by low plasma cortisol con-
centrations because the zona fasciculata is primarily
responsible for glucocorticoid production. Low circulat-
ing serum cortisol results in a lack of feedback inhibi-
tion to the hypothalamus; markedly increased ACTH
levels are often observed. Because the zona glomerulosa
is generally well preserved, mineralocorticoid production
is usually unaffected. Plasma renin and aldosterone con-
centrations are usually within the reference range in the
baseline state and demonstrate normal variability on salt
restriction [3].
FGD may be caused by mutations in the gene of the
ACTH receptor (melanocortin 2 receptor; MC2R), classi-
fied as FGD type 1, or by mutations in the melanocortin-
2 receptor accessory protein (MRAP), classified as FGD
type 2. Mutations of the ACTH receptor (type 1) account
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approximately 15% to 20% of FGD cases [4]. These muta-
tions may affect ACTH signal transduction, expression of
the ACTH receptor or differentiation of the adrenal
cortex [5].
Case presentation
An 18-month-old Egyptian boy was referred to our
pediatric endocrinology clinic for evaluation of general-
ized hyperpigmentation of the skin associated with
weakness, vomiting and recurrent convulsions. He was
born to consanguineous parents after an uneventful
pregnancy with a birth weight of 3450 g. He was the
fourth child of the family; one of his siblings, who had
died of an unknown cause at the age of nine months,
had generalized hyperpigmentation of the body, recur-
rent convulsions and mental retardation. His other sib-
lings were reported to be healthy.
After the first few weeks of the baby’s life, his mother
noticed a generalized black coloration of his skin. His
parents also reported that he was darker than his sister
and brother. At the ages of 10 and 11 months he had two
attacks of a febrile brief generalized tonic-clonic convul-
sion. The etiology of the convulsions had not been evalu-
ated as the parents did not seek medical advice at that
time. On examination, our patient was able to speak only
a few words and walk with support. His weight was in
the 5
th percentile while his length and head circumfer-
ence were in the 50
th percentile. His blood pressure was
90/60 mmHg. Unlike his fair-skinned parents, he had
generalized symmetric deep hyperpigmentation of the
body, especially of his elbows, knees, hands, feet and buc-
cal mucosa (Figures 1 and 2), as well as hypotonia. He
had no dysmorphic features. Examination of his external
genitalia revealed a penis of normal length and bilaterally
palpable testes in his scrotum. There were no signs of
alacrima or achalasia. Other examination findings were
unremarkable.
His blood chemistry results were: glucose, 48 mg/dL;
sodium, 140 mmol/L; potassium, 4 mmol/L; chloride, 109
mmol/L; alanine transaminase, 28 IU/mL; and aspartate
transaminase, 30 IU/mL. His total blood count was normal.
His cortisol level was 0.6 μg/dL (normal range: 2.8 to
23 μg/dL) and ACTH, 708 pg/mL (normal range: 6 to
48 pg/mL). An ACTH stimulation test did not cause a rise
in his cortisol level. His 17-OH progesterone level was
0.01 ng/mL (normal range: 0.03 to 0.9 ng/mL); androstene-
dione, 0.01 ng/mL (normal range: 0.1 to 0.17 ng/mL),
dehydroepiandrosterone, 3 ng/mL (normal range: 50
to 480 ng/mL); plasma rennin activity, 57 ng/mL/hour
(normal range: 2.35 to 37 ng/mL/hour); aldosterone,
801 pg/mL (normal range: 50 to 900 pg/mL).
His bone age, evaluated by an X-ray of his left hand
and wrist according to the Greulich-Pyle atlas, was
equivalent to two years. Adrenal ultrasonography
revealed that both his adrenal glands were small; his left
was 6 × 8 mm and right 7 × 8 mm in diameter. Compu-
terized tomography of his brain was normal. A molecu-
lar genetics study revealed normal ACTH receptor gene
sequences, excluding FGD type 1, and a homozygous
deletion (c. 111+1delG) in intron 3 of the MRAP gene
was detected. Based on these findings, a diagnosis of
FGD type 2 was made. Oral hydrocortisone treatment at
a dose of 10 mg/m
2/day was started.
Our patient was seen two months after starting treat-
ment. His general condition was greatly improved and he
was able to walk alone. The hyperpigmentation was less in
comparison with his initial presentation (Figures 3 and 4),
he had gained 1500 g, and his blood sugar and cortisol
levels were normalized while the level of ACTH had
dropped to 221 pg/mL.
Discussion
Unawareness of FGD can lead to delay in diagnosis, not
only in the affected patient but also among other mem-
bers of the family. The disorder can be fatal if proper
treatment is not provided. FGD should be distinguished
from other causes of adrenal insufficiency, which
include congenital adrenal hyperplasia, adrenal hypopla-
sia, adrenoleukodystrophy, Allgrove syndrome, adrenal
hemorrhage, trauma and infections, by taking a thor-
ough history, clinical examination and appropriate
investigations [6].
A review of the literature revealed that the age of onset
of symptoms in patients with FGD ranges from birth to
nine years old. All the symptoms and signs seen in FGD
are the result of either hypocortisolemia or elevated
ACTH levels, of which our patient had both. Hypocortiso-
lemia may cause weakness, fatigue, weight loss, anorexia
progressing to nausea, vomiting, diarrhea, constipation,
flank or abdominal pain, hypoglycemia and hypothermia.
High ACTH causes increased melanin production, result-
ing in generalized hyperpigmentation and advanced bone
age [7,8]. Bone age was advanced by four months in our
patient, which may be attributed to increased ACTH or
related pathophysiologic changes [4]. The long-term neu-
rological consequence of FGD can vary from learning diffi-
culties to spastic quadriplegia, which may reflect the
severity and number of hypoglycemic episodes during
childhood [9]. The most frequent cause of FGD death is
undiagnosed glucocorticoid insufficiency. Although this
disease is easily treatable when recognized, if left untreated
it may be fatal or lead to severe mental disability as a result
of recurrent hypoglycemia secondary to glucocorticoid
insufficiency.
Our patient was diagnosed with FGD at the age of 18
months; he had two attacks of convulsive episodes prior
to the presentation that could be attributed to
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reported an Ethiopian infant with FGD, who presented
with psychomotor retardation, spastic quadriparesis and
microcephaly due to severe hypoglycemic attacks.
Our patient was diagnosed with FGD type 2 by a mole-
cular genetics study, through detection of mutations in the
MRAP gene (OMIM 607398). MRAP, located at 21q22.1,
is an essential cofactor for MC2R expression in certain cell
Figure 1 Hyperpigmentation of the upper limb before treatment.
Figure 2 Hyperpigmentation of the foot before treatment.
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ing or function of MC2R [5]. MRAP has two isoforms,
namely MRAPa and MRAPb, that differentially regulate
the function of MC2R [10]. Akin et al. [6] reported a
Turkish patient with FGD type 2, with a known MRAP
mutation. Their patient was the offspring of consangui-
neous parents and his four siblings had died in the neona-
tal period, probably due to glucocorticoid insufficiency.
Figure 3 Improvement in hyperpigmentation of the upper limb after treatment.
Figure 4 Improvement in hyperpigmentation of the lower limbs after treatment.
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cortisone. An oral dose of 10 to 12 mg/m
2/day in three
divided doses is usually sufficient. The suppression of
plasma ACTH levels in FGD can be very difficult and
should not be used as the goal of treatment. Educating
parents and patients on the need to increase hydrocorti-
sone dosages during illness and emergency management
with intramuscular hydrocortisone is vital [11]. In addi-
tion, replacement with hydrocortisone in children with
FGD should not be a contraindication to vaccinate with
live attenuated vaccines [12].
Conclusion
FGD is a rare, treatable disease that can be easily missed
due to its nonspecific presentation. The consequences of
delayed diagnosis and treatment are associated with
high rates of morbidity and mortality. Clinical awareness
of this condition is of considerable prognostic and ther-
apeutic significance.
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